Drug Trial Radar · NCT07605962
Phase 1/2 Study of UI-102 in Selected Advanced Cancers
Last checked: Nov 19, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
140
Planned (sponsor's estimate)
Start
May 20, 2026
Primary completion
Mar 31, 2030
Study completion Mar 31, 2031
Sponsor
- Lead sponsor
- United Immunity, co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 26, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase 1/2 first-in-human study is designed to assess the safety and efficacy of UI-102, a TLR7/8 agonist encapsulated in a Cholesteryl Pullulan Nanoparticle.
Conditions
- Advanced Cancer
Interventions
UI-102Drug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation: Percentage of participants with ≥1 dose-limiting toxicity (DLT)Time frame: Up to 24 months
- Dose Escalation: Percentage of participants with ≥1 adverse event (AE)Time frame: Up to 24 months
- Dose Escalation: Percentage of participants with ≥1 serious adverse event (SAE)Time frame: Up to 24 months
- Dose Escalation: Percentage of participants with significant changes in electrocardiogram (ECG) recordingsTime frame: Up to 24 months
- Dose Escalation: Percentage of participants with significant changes in vital signsTime frame: Up to 24 months
- Dose Escalation: Percentage of participants with significant changes in laboratory resultsTime frame: Up to 24 months
- Dose Escalation: Percentage of participants with a dose interruption, reduction, or discontinuationTime frame: Up to 24 months
- Expansion: Best Overall Response (BOR) as Determined by RECIST v1.1Time frame: Up to 48 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
NEXT Oncology
Dallas, Texas · Recruiting
NEXT Oncology
Houston, Texas · Recruiting
NEXT Oncology
San Antonio, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.